Legislation attached to the government spending package reauthorized the Pediatric Priority Review Voucher (PPRV) program through 2029 and included provisions aimed at pharmacy benefit manager (PBM) reform and transparency. BIO praised the reauthorization as a bipartisan victory that preserves incentives for pediatric rare‑disease development, and the package’s PBM measures seek to curb rebate‑linked pricing distortions. Lawmakers and industry groups framed the outcome as stabilizing policy for rare‑disease sponsors and addressing middle‑man pricing practices.